



PATENT
Attorney Docket No. 209897
DHHS Reference No. E-103-2000/0-US-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lazarus et al.

Application No. 09/814,558

Filed: March 22, 2001

For: DMT-TIC DI- AND TRI-PEPTIDIC
DERIVATIVES AND RELATED
COMPOSITIONS AND METHODS OF
USE

Art Unit: 1653

Examiner: D. Lukton

RESPONSE TO OFFICE ACTION

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated January 28, 2004, please consider the following remarks.

CERTIFICATE OF MAILING UNDER 37 CFR 1.8			
I hereby certify that this Response to Office Action and all accompanying documents are, on the date indicated below, being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
Name (Print/Type)	Kristen J. Harrell		
Signature	Kristen J. Harrell	Date	April 20, 2004


REMARKS

Claim 11 is rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite. According to the Office, claim 11 is indefinite because the nature of the receptor antagonism is not specified.

Applicants thank Examiner Lukton for courtesies extended to Applicants' representative, Kristen J. Harrell, on January 26, 2004. The wording of a proposed amendment to claim 11 was discussed. Since the proposed amendment to claim 11 was entered by Examiner's Amendment, and a Notice of Allowability was issued February 9, 2004, the indefiniteness rejection appears to be moot.

Applicants understand that no further action is required with respect to the Office Action dated January 28, 2004.

Respectfully submitted,



Kristen J. Harrell, Reg. No. 51,783
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: April 20, 2004